

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION

Women's GLN-MINOXIDIL

Minoxidil Foam 50 mg/g (5%w/w)
Topical

Hair Regrowth Treatment

Glenmark Pharmaceuticals Canada Inc.
1600 Steeles Ave. West., Suite 407
Concord, ON L4K 4M2

Date of Authorization:
March 05, 2025

Submission Control Number: 288718

TABLE OF CONTENTS

Sections or subsections that are not applicable at the time of authorization are not listed.

TABLE OF CONTENTS	2
PART I: HEALTH PROFESSIONAL INFORMATION	4
1 INDICATIONS	4
1.1 Pediatrics.....	4
1.2 Geriatrics	4
2 CONTRAINDICATIONS	4
4 DOSAGE AND ADMINISTRATION	5
4.1 Dosing Considerations	5
4.2 Recommended Dose and Dosage Adjustment	5
4.4 Administration.....	5
4.5 Missed Dose.....	5
5 OVERDOSAGE	6
6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING	7
7 WARNINGS AND PRECAUTIONS	7
7.1 Special Populations	8
7.1.1 Pregnant Women.....	8
7.1.2 Breast-feeding	8
7.1.3 Pediatrics	8
8 ADVERSE REACTIONS	8
8.1 Adverse Reaction Overview	8
8.2 Clinical Trial Adverse Reactions.....	10
8.5 Post-Market Adverse Reactions.....	15
9 DRUG INTERACTIONS	17
9.2 Drug Interactions Overview	17
9.3 Drug-Behavioural Interactions.....	17
9.4 Drug-Drug Interactions	17
9.5 Drug-Food Interactions.....	17

9.6	Drug-Herb Interactions	17
9.7	Drug-Laboratory Test Interactions.....	18
10	CLINICAL PHARMACOLOGY.....	18
10.1	Mechanism of Action	18
10.2	Pharmacodynamics.....	18
10.3	Pharmacokinetics	19
11	STORAGE, STABILITY AND DISPOSAL	23
13	PHARMACEUTICAL INFORMATION	24
14	CLINICAL TRIALS.....	24
14.1	Clinical Trials by Indication	24
14.2	Study Results	26
14.3	Comparative Bioavailability Studies.....	27
15	MICROBIOLOGY	27
16	NON-CLINICAL TOXICOLOGY	28
17	SUPPORTING PRODUCT MONOGRAPHS	34
PATIENT MEDICATION INFORMATION		35

PART I: HEALTH PROFESSIONAL INFORMATION

1 INDICATIONS

Women's GLN-MINOXIDIL (5% minoxidil topical foam) is indicated for:

- the treatment of female androgenetic alopecia (female pattern hair loss) on the top of the scalp.

The effectiveness of Women's GLN-MINOXIDIL in the treatment of receding hairlines has not been demonstrated in clinical trials.

Persistence of effect while using Women's GLN-MINOXIDIL has been demonstrated for 24 weeks in clinical trials.

1.1 Pediatrics

Pediatrics (<18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use.

1.2 Geriatrics

Geriatrics (>65 years of age): Women's GLN-MINOXIDIL has been found to be safe and effective in women up to the age of 87 years.

2 CONTRAINDICATIONS

Women's GLN-MINOXIDIL is contraindicated:

- in Women who are pregnant or breastfeeding or have hair loss associated with childbirth.
- in individuals with a history of hypersensitivity to minoxidil or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see [6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING](#).
- in individuals with treated or untreated hypertension.
- in individuals whose baldness is not due to hereditary factors. Women's GLN-MINOXIDIL is only effective for the treatment of hair loss on the top of the scalp (female pattern hair loss).
- in individuals with any scalp abnormality (including psoriasis and sunburn).
- in individuals with a shaved scalp or whose scalp's skin is broken, inflamed, irritated, infected, or severely sunburned.
- if occlusive dressings or other topical therapeutic medications for treating disorders of the skin of the scalp are being used.

Certain prescription and non-prescription medications, recent discontinuation of birth control medication, certain treatments, such as cancer chemotherapy, or certain diseases, such as

iron deficiency, thyroid disorders or secondary syphilis, as well as severe nutritional problems and certain grooming habits (e.g., cornrowing, tight ponytails), may also cause temporary hair loss which should not be treated with Women's GLN-MINOXIDIL.

4 DOSAGE AND ADMINISTRATION

4.1 Dosing Considerations

- FOR EXTERNAL USE ONLY.

4.2 Recommended Dose and Dosage Adjustment

Women's GLN-MINOXIDIL

Apply half (½) capful foam (50 mg minoxidil) on a clean non-absorbent surface such as a dish. Make a centre part within the hair thinning areas to help maximize scalp exposure. Part the hair at least 2 more times on each side of the centre part around the thinning area. Spread the foam with the fingertips over the hair loss scalp areas and gently massage foam into the scalp starting from the back to front (forehead) direction. Massage until all the foam dose is gone. After each use, thoroughly clean and dry the non-absorbent surface to which the foam was placed before applying to the scalp. The hands should be washed well with soap and water after the application. Allow Women's GLN-MINOXIDIL to remain on scalp for at least 4 hours for best results.

Health Canada has not authorized an indication for pediatric use.

4.4 Administration

Women's GLN-MINOXIDIL

- 1) To open container: Match arrow on can ring with arrow on cap. Pull off cap.
- 2) Hold the can upside down and press nozzle to dispense the foam. The total amount of foam applied should not exceed half (½) capful (equivalent to one gram of foam).
- 3) The foam may begin to melt on contact with warm skin. If your fingers are warm, rinse them in cold water first. Be sure to dry them thoroughly before handling the foam.
- 4) The foam should be massaged lightly into the affected areas of the scalp.

4.5 Missed Dose

Women's GLN-MINOXIDIL

If one or two applications are missed, the missed application(s) should be skipped, and treatment should be resumed with the next scheduled application/dose. Do not use twice as much, or twice as often, the prescribed dose.

5 OVERDOSAGE

Accidental ingestion of Women's GLN-MINOXIDIL can cause serious cardiac adverse effects. Contact your regional Poison Control Centre immediately.

Because of the high concentration of minoxidil in Women's GLN-MINOXIDIL, accidental oral ingestion of these products could result in systemic absorption sufficient to cause the predictable cardiovascular effects of minoxidil (e.g., reduced blood pressure, reflex tachycardia, fluid retention).

Signs and symptoms of overdosage would most likely include cardiovascular effects associated with fluid retention, sudden weight gain, lowered blood pressure and tachycardia, faintness and dizziness. Fluid retention can be managed with appropriate diuretic therapy. Tachycardia can be controlled by administration of beta-adrenergic blocking agent.

Minoxidil and its metabolites are hemodialyzable, although this does not rapidly reverse its pharmacological effect.

Significant toxicity after minoxidil exposure, whether tablet or topical formulations, was associated with oral route, intentional reason, and co-ingestion of other products. A male who ingested 60 mL (one bottle) of 2% minoxidil with 12 ounces of cognac experienced tachycardia, hypotension, and a non-Q wave myocardial infarction. In another report, a patient who inadvertently drank minoxidil solution (he ingested 600 mg), developed syncope, hypotension, and acute renal failure.

There have been 27 spontaneous reports of unintentional oral exposure to minoxidil solution involving 12 pediatric patients and 15 adults. No adverse events were associated with 17 of the reports. Of the remaining 10 cases, one pediatric patient experienced lethargy, one pediatric patient had flushed cheeks, and one pediatric patient was more active and had diarrhea. One adult patient had tachycardia in addition to nausea and vomiting.

If exaggerated hypotension is encountered, it is most likely to occur in association with residual sympathetic nervous system blockade from previous therapy (guanethidine-like effects or alpha-adrenergic blockade). The recommended treatment is intravenous administration of normal saline.

Sympathomimetic drugs, such as norepinephrine or epinephrine, should be avoided because of their excessive cardiac-stimulating action. Phenylephrine, angiotensin II, vasopressin and dopamine, which reverse the effects of orally administered minoxidil, should only be used if inadequate perfusion of a vital organ is evident.

For the most recent information in the management of a suspected drug overdose, contact your regional poison control centre or Health Canada's toll-free number, 1-844 POISON-X (1-844-764-7669).

6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

Table – Dosage Forms, Strengths, Composition and Packaging

Route of Administration	Dosage Form / Strength/Composition	Non-medicinal Ingredients
Topical	Foam / 50 mg/g (5%) minoxidil	Anhydrous Citric Acid, Butylated Hydroxyl Toluene, Cetyl Alcohol, Dehydrated Alcohol, Glycerin, Hydrocarbon Propellant (propane, isobutane, n-butane), L-Lactic Acid, Purified Water, Polysorbate 60, and Stearyl Alcohol.

Women's GLN-MINOXIDIL (5% minoxidil topical foam) is available in a lined (polyamide-imide) aluminium pressurized container with a translucent round dust cap, containing 60 grams of product. Packs contain either one or three cans. The foam is creamy in appearance.

7 WARNINGS AND PRECAUTIONS

General

- Women's GLN-MINOXIDIL is for external use only. Apply only to scalp.
- Before applying Women's GLN-MINOXIDIL, the user should determine that the scalp is normal and healthy.
- Hands should be washed thoroughly after use.
- Inhalation of the spray should be avoided.
- Women's GLN-MINOXIDIL contain ethanol (alcohol) which will cause burning and irritation of the eye. In the event of accidental contact with sensitive surfaces (eye, abraded skin, mucous membranes), the area should be bathed with large amounts of cool tap water.
- Women's GLN-MINOXIDIL also contain butylated hydroxytoluene, cetyl alcohol, and stearyl alcohol. Butylated hydroxytoluene may cause local skin reactions (e.g., contact dermatitis), or irritation to the eyes or mucous membranes. Cetyl alcohol and stearyl alcohol may cause local skin reactions (e.g., contact dermatitis).
- Some patients have experienced changes in hair colour and/or texture with Women's GLN-MINOXIDIL use.
- Shedding of hair may occur within two to six weeks after initiating therapy, likely due to minoxidil's action on shifting hairs from the resting telogen phase to the growing anagen phase. If shedding persists for more than two weeks, users should stop applying Women's GLN-MINOXIDIL and consult their doctor.
- Women's GLN-MINOXIDIL should not be used when there is no family history of hair loss, hair loss is sudden and/or patchy, or the reason for hair loss is unknown.

Cardiovascular

- Patients with known cardiovascular disease or cardiac arrhythmia should contact a physician before using Women's GLN-MINOXIDIL.
- Although the following systemic effects have not been associated with the topical use of

Women's GLN-MINOXIDIL, there is some absorption of minoxidil from the skin and the potential exists for systemic effects such as salt and water retention, hypertension, tachycardia, angina, and edema.

- The patient should stop using Women's GLN-MINOXIDIL and see a doctor if hypotension is detected or if the patient is experiencing chest pain, rapid heartbeat, faintness or dizziness, sudden unexplained weight gain, swollen hands or feet, or persistent redness.

Monitoring and Laboratory Tests

Patients should be monitored for signs of systemic effects of minoxidil such as hypotension, chest pain, rapid heartbeat, faintness or dizziness, sudden unexplained weight gain, swollen hands or feet, persistent redness or irritation of the scalp. The use of Women's GLN-MINOXIDIL should be discontinued in the event of systemic effects and/or severe dermatologic reactions.

7.1 Special Populations

7.1.1 Pregnant Women

There are no adequate and well-controlled studies in pregnant women using Women's GLN-MINOXIDIL. This product should not be used in pregnant women.

7.1.2 Breast-feeding

Systemically absorbed minoxidil is secreted in human milk. Women's GLN-MINOXIDIL should not be used in nursing women.

7.1.3 Pediatrics

Pediatrics (<18 years of age): The efficacy and safety of Women's GLN-MINOXIDIL in children under 18 years of age has not been established. This product should not be used in the pediatric population.

8 ADVERSE REACTIONS

8.1 Adverse Reaction Overview

Women's GLN-MINOXIDIL

The clinical trial safety database comprises a total of 942 subjects, of whom 576 were treated with one or more formulations of 5% Minoxidil Topical Foam (MTF).

In the placebo-controlled phase 3 study of efficacy and safety (MINALO3005), patterns of adverse events indicated that both 5% MTF once daily and foam vehicle were well tolerated by the subjects. No difference in the overall incidence of adverse events between treatment groups (approximately 50% of subjects in each group) was observed. The incidence of specific adverse events was generally similar between the treatment groups. The most commonly experienced adverse events (occurring in $\geq 5.0\%$ of subjects) in the 5% MTF once daily and foam vehicle groups were weight increased (8.4% and 7.0%, respectively) and nasopharyngitis (5.4% and 6.5%, respectively).

In the active-controlled phase 3 study of efficacy and safety (MINALO3004), patterns of adverse events indicated that both 5% MTF once daily and 2% Minoxidil Topical Solution (MTS) applied twice daily were well tolerated by the subjects. The overall incidence of adverse events was similar between treatment groups (67.7% in 5% MTF once daily and 73.3% in 2% MTS twice daily). The most commonly ($\geq 5.0\%$ of subjects) experienced adverse events in the 5% MTF once daily group were nasopharyngitis (14.3%), weight increased (12.4%), upper respiratory tract infection (9.9%), sinusitis (6.2%), headache (5.6%), urinary tract infection (5.0%), and bronchitis (5.0%). The most commonly experienced adverse events in the 2% MTS twice daily group were nasopharyngitis (13.7%), headache (9.9%), weight increased (8.7%), sinusitis (7.5%), and upper respiratory tract infection (5.0%).

In MINOB-9140-004, because subjects received all study medications simultaneously via skin patches, no comparison of adverse event incidences between treatments is possible. In MINOB-9140-001, the numbers of subjects receiving 2% MTS or 5% MTS were too small to allow meaningful comparison of adverse event rates between treatments.

In addition, in the phase 3 studies, serum minoxidil concentrations were to be determined at the investigator's discretion for any subject having a cardiovascular adverse event during the study. Serum minoxidil levels from such testing were found to be below the threshold associated with hemodynamic events. The timing of the collection of these samples varied depending on when the subject had the cardiovascular event. If the event occurred in-between study visits, then the subject was required to come to the office as soon as possible for an unscheduled visit.

In MINALO3005, 2 subjects in the 5% MTF once daily group died within 30 days after the last dose of investigational product (IP) due to non-investigational-product-related causes (cardiovascular disorder in 1 subject and dehydration and renal failure in 1 subject). No deaths occurred during MINALO3004 within 30 days after the last dose of IP. However, 1 subject in the 2% MTS BID group experienced a serious adverse event of metastatic neoplasm that led to death 140 days after the last dose of IP. This serious adverse event was considered to be not IP related.

The percentage of subjects experiencing serious adverse events in the phase 3 studies was low. All serious adverse events were considered by the investigator to have a doubtful relationship or to be not related to IP. In the 4 clinical studies, the incidence of drug-related adverse events was low overall. Pruritus (1.5% of subjects) was the only drug-related treatment-emergent adverse event occurring in $\geq 1.0\%$ of the subjects across the 4 studies.

The incidence of adverse events leading to study withdrawal was low overall. Headache (2 subjects overall) and pruritus (2 subjects overall) were the only adverse events causing subjects to discontinue that were reported in more than 1 subject across the 4 studies.

Data from the phase 3 studies indicated a low incidence of hypertrichosis. In MINALO3005, hypertrichosis was recorded as an adverse event for one subject in both the 5% MTF once daily and foam vehicle groups. In MINALO3004, hypertrichosis was recorded as an adverse event for 3 subjects in the 5% MTF once daily group.

Analysis of clinical laboratory test results, vital signs, and physical examination findings revealed no new or unexpected safety issues relevant to the intended use of 5% MTF once daily.

Overall safety analyses in the 4 clinical trials have shown 5% MTF once daily to be well tolerated in

healthy subjects and in women with FPHL who were treated for up to 52 weeks. The safety profile of 5% MTF in females was generally similar to that observed in clinical trials of 5% MTF BID in males and 5% Minoxidil Topical Solution applied twice daily in males. No new or unusual findings were reported in the phase 3 studies.

In general, the overall post-marketing safety experience to date has been consistent with that observed in the clinical trial program.

8.2 Clinical Trial Adverse Reactions

Clinical trials are conducted under very specific conditions. The adverse reaction rates observed in the clinical trials; therefore, may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials may be useful in identifying and approximating rates of adverse drug reactions in real-world use.

Women's MINOXIDIL

Table 1: Treatment-Emergent Adverse Events Reported by ≥ 1.0% of Subjects in the Foam Vehicle, 2% MTS Twice Daily, or 5% MTF Once Daily Groups in MINALO3004 or MINALO3005 (Intent-to Treat Subjects)

System Organ Class Preferred Term	Number (%) of Subjects			
	MINALO3004		MINALO3005	
	2% MTS Twice Daily	5% MTF Once Daily	Foam Vehicle Once Daily	5% MTF Once Daily
	52 weeks (N=161)	52 weeks (N=161)	24 weeks (N=201)	24 weeks (N=203)
Subjects experiencing ≥ 1 AE	116 (72.0)	109 (67.7)	96 (47.8)	99 (48.8)
Ear and labyrinth disorders	3(1.9)	1(< 1)	0	2(<1)
Vertigo	2(1.2)	0	0	1(<1)
Endocrine disorders	2(1.2)	1(< 1)	1(< 1)	1(<1)
Hypothyroidism	2(1.1)	1(< 1)	0	1(<1)
Gastrointestinal disorders	23(14.3)	9(5.6)	6(3.0)	9(4.4)
Abdominal pain upper	4(2.5)	0	0	1(<1)
Diarrhea	2(1.2)	4(2.5)	0	0
Gastroesophageal reflux disease	2(1.2)	0	0	1(<1)
Nausea	3(1.9)	2(1.2)	1(<1)	0
Toothache	4(2.5)	1(<1)	1(<1)	2(<1)
General disorders and administration site conditions	10(6.2)	12(7.5)	3(1.5)	5(2.5)
Influenza like illness	3(1.9)	4(2.5)	0	0

Number (%) of Subjects				
System Organ Class Preferred Term	MINALO3004		MINALO3005	
	2% MTS Twice Daily	5% MTF Once Daily	Foam Vehicle Once Daily	5% MTF Once Daily
	52 weeks	52 weeks	24 weeks	24 weeks
	(N=161)	(N=161)	(N=201)	(N=203)
Edema peripheral	1(<1)	3(1.9)	0	1(<1)
Pain	1(<1)	2(1.2)	0	0
Pyrexia	2(1.2)	1(<1)	0	1(<1)
Infections and infestations	61(37.9)	61(37.9)	36(17.9)	40(19.7)
Bronchitis	2(1.2)	8(5.0)	0	2(<1)
Cystitis	4(2.5)	4(2.5)	2(<1)	1(<1)
Gastroenteritis	4(2.5)	2(1.2)	1(<1)	6(3.0)
Gastroenteritis viral	3(1.9)	2(1.2)	0	1(<1)
Herpes zoster	2(1.2)	0	1(<1)	0
Influenza	3(1.9)	3(1.9)	3(1.5)	2(<1)
Nasopharyngitis	22(13.7)	20(12.4)	13(6.5)	9(4.4)
Sinusitis	12(7.5)	10(6.2)	4(2.0)	7(3.4)
Tooth abscess	2(1.2)	2(1.2)	1(<1)	0
Tooth infection	2(1.2)	0	0	2(<1)
Upper respiratory tract infection	7(4.3)	16(9.9)	7(3.5)	5(2.5)
Urinary tract infection	3(1.9)	8 (5.0)	1(<1)	4(2.0)
Injury, poisoning and procedural complications	21 (13.0)	20(12.4)	5(2.5)	10(4.9)
Arthropod bite	2(1.2)	3(1.9)	2(<1)	0
Contusion	1(<1)	2(1.2)	0	0
Fall	3(1.9)	3(1.9)	0	2(<1)
Laceration	1(<1)	2(1.2)	0	0
Ligament sprain	2(1.2)	0	2(<1)	1(<1)
Limb injury	0	2(1.2)	0	0
Muscle strain	2(1.2)	1(<1)	0	2(<1)
Procedural pain	6(3.7)	4(2.5)	0	0
Investigations	16(9.9)	23(14.3)	16(8.0)	19(9.4)
Weight increased	14(8.7)	20(12.4)	13(6.5)	16(7.9)

Number (%) of Subjects				
System Organ Class Preferred Term	MINALO3004		MINALO3005	
	2% MTS Twice Daily	5% MTF Once Daily	Foam Vehicle Once Daily	5% MTF Once Daily
	52 weeks	52 weeks	24 weeks	24 weeks
	(N=161)	(N=161)	(N=201)	(N=203)
Metabolism and nutrition disorders	3(1.9)	4(2.5)	2(<1)	4(2.0)
Hypercholesterolemia	1(<1)	2(1.2)	1(<1)	0
Musculoskeletal and connective tissue disorders	17(10.6)	17(10.6)	10(5.0)	11(5.4)
Arthralgia	4(2.5)	2(1.2)	1(<1)	1(<1)
Arthritis	1(<1)	2(1.2)	0	0
Back pain	5(3.1)	7(4.3)	2(<1)	4(2.0)
Neck pain	0	2(1.2)	0	1(<1)
Pain in extremity	1(<1)	3(1.9)	1(<1)	0
Nervous system disorders	22(13.7)	16(9.9)	12(6.0)	8(3.9)
Carpal tunnel syndrome	2(1.2)	0	0	0
Dysgeusia	2(1.2)	0	0	0
Headache	16 (9.9)	9(5.6)	7(3.5)	6(3.0)
Migraine	2(1.2)	1(<1)	1(<1)	1(<1)
Paresthesia	0	2(1.2)	0	0
Syncope	0	2(1.2)	0	1(<1)
Psychiatric disorders	5(3.1)	3(1.9)	2(<1)	2(<1)
Anxiety	2(1.2)	1(<1)	0	1(<1)
Respiratory, thoracic and mediastinal disorders	14(8.7)	8(5.0)	2(<1)	3(1.5)
Asthma	2(1.2)	0	0	0
Cough	5(3.1)	4(2.5)	1(<1)	1(<1)
Nasal congestion	2(1.2)	0	0	1(<1)
Oropharyngeal pain	0	4(2.5)	0	0
Rhinitis allergic	2(1.2)	0	0	0
Sleep apnea syndrome	2(1.2)	0	0	0
Skin and subcutaneous tissue disorders	24(14.9)	23(14.3)	11(5.5)	17(8.4)

Number (%) of Subjects				
System Organ Class Preferred Term	MINALO3004		MINALO3005	
	2% MTS Twice Daily	5% MTF Once Daily	Foam Vehicle Once Daily	5% MTF Once Daily
	52 weeks	52 weeks	24 weeks	24 weeks
	(N=161)	(N=161)	(N=201)	(N=203)
Acne	2(1.2)	2(1.2)	0	0
Actinic keratosis	1(<1)	2(1.2)	0	0
Alopecia	4(2.5)	4(2.5)	0	1(<1)
Dermatitis	2(1.2)	2(1.2)	0	0
Dermatitis contact	3(1.9)	0	1(<1)	1(<1)
Eczema	2(1.2)	2(1.2)	0	2(<1)
Erythema	1(<1)	2(1.2)	0	1(<1)
Hypertrichosis	0	3(1.9)	1(<1)	1(<1)
Pain of skin	2(1.2)	1(<1)	0	1(<1)
Pruritus	4(2.5)	4(2.5)	3(1.5)	3(1.5)
Rash papular	2(1.2)	0	0	0
Urticaria	2(1.2)	1(<1)	0	2(<1)
Vascular disorders	5(3.1)	7(4.3)	5(2.5)	4(2.0)
Hypertension	3(1.9)	5(3.1)	5(2.5)	2(<1)

Serious Adverse Events in MINALO3004 and MINALO3005

In MINALO3004, a greater percentage of subjects in the 2% MTS twice daily group (5.0%) compared to subjects in the 5% MT once daily group (1.2%) experienced at least one serious adverse event (SAE).

In MINALO3005, similar percentages of subjects in the 5% MTF once daily group (3.0%) and the foam vehicle group (2.0%) experienced at least one SAE.

No pattern was observed for the types of SAEs reported in either study.

Two subjects in the 5% MTF once daily group died within 30 days after the last dose of investigational product (IP) due to non-IP-related causes (cardiovascular disorder in one subject and dehydration and renal failure in another subject).

No deaths occurred during MINALO3004 within 30 days after the last dose of IP. However, one subject in the 2% MTS BID group experienced an SAE of metastatic neoplasm that led to death 140 days after the last dose of IP.

Studies (MINALO3004, MINALO3005, MINOB-9140-001, MINOB-9140-004)

Treatment-emergent Adverse Events

A total of 942 female subjects were treated with one or more formulations of 5% MTF, 2% MTS, and/or foam vehicle in the 4 clinical studies included in the table below. Three of the 4 studies included subjects with female pattern hair loss (FPHL) (n=760) and the fourth study included normal, healthy volunteers (n=182). Most subjects (80.7%) were white. The mean age of the study population was 53.9 years (range: 18-87 years). MINALO3004 involved once daily dosing of 5% MTF versus twice daily dosing of 2% MTS. MINALO3005 involved once daily application of 5% versus once daily application of placebo vehicle. MINOB-9140-001 was a randomized, crossover, open label clinical investigation of two 5% MTF formulations and 2% MTS in 34 female subjects. MINOB-9140-004 was a single-centre, randomized evaluator-blind study to evaluate contact sensitization potential with repeated drug- patch application. Three 5% MTF formulations (unscented, sport fragrance, and floral fragrance) and a foam vehicle (unscented) were evaluated in 182 female subjects.

Safety assessments for the above mentioned four studies were based on standard safety measure (adverse events, clinical laboratory tests, vital signs determinations, and, as appropriate for a topical medication, assessments of skin irritation).

The following table lists treatment-emergent adverse events (AEs) that were reported in $\geq 1.0\%$ of the subjects in descending order of frequency, and drug-related treatment-emergent AEs reported in ≥ 2 subjects. Overall, 47.5% (447/942) of the subjects experienced ≥ 1 treatment emergent AE. Nasopharyngitis was the most commonly reported treatment-emergent AE (7.1% of subjects). Weight increased (6.7%), headache (4.0%), upper respiratory tract infection (3.7%), and sinusitis (3.5%) were the only other treatment-emergent AEs reported in $\geq 2\%$ of subjects. Pruritus (1.5% of subjects) was the only drug-related treatment-emergent AE occurring in $\geq 1.0\%$ of the subjects. Asthenia was the only SAE (2 foam vehicle subjects in MINALO3005), and headache (one 2% MTS BID subject in MINALO3004 and 5% MTF once daily subject in MINALO3005) and pruritus (1 subject) in MINOB-9140-004 and 5% MTF once daily subject in MINALO3004) were the only AEs causing subjects to discontinue that were reported in more than one subject.

Table 2: Treatment-Emergent Adverse Events in MINOB-9140-001, MINOB-9140-004, MINALO3004, and MINALO3005 (Intent- to-Treat Subjects)

Preferred Term	TEAE ^a	Drug-Related TEAE ^b	SAE ^c	AE Leading to Discontinuation ^c
Total number of subjects ^d	942	942	942	942
Subjects experiencing >1 AE	447(47.5)	64(6.8)	20(2.1)	24(2.5)
Nasopharyngitis	67(7.1)	0	0	0
Weight increased	63(6.7)	0	0	0
Headache	38(4.0)	7(<1)	0	2(<1)
Upper respiratory tract infection	35(3.7)	0	0	0

Preferred Term	TEAE ^a	Drug-Related TEAE ^b	SAE ^c	AE Leading to Discontinuation ^c
Sinusitis	33(3.5)	0	0	0
Back pain	18(1.9)	0	0	0
Urinary tract infection	16(1.7)	0	0	0
Pruritus	15(1.6)	14(1.5)	0	2(<1)
Hypertension	15(1.6)	1(<1)	0	1(<1)
Bronchitis	14(1.5)	0	0	0
Gastroenteritis	13(1.4)	0	0	0
Toothache	11(1.2)	0	0	1(<1)
Cystitis	11(1.2)	0	0	0
Influenza	11(1.2)	0	1(<1)	0
Cough	11(1.2)	0	0	0
Procedural pain	10(1.1)	0	0	0
Application site pain		2(<1)		
Alopecia		7(<1)		
Dry skin		2(<1)		
Eczema		4(<1)		
Erythema		2(<1)		
Hair texture abnormal		2(<1)		
Hypertrichosis		5(<1)		
Pain of skin		3(<1)		
Asthenia			2(<1)	

AE= adverse event; SAE=serious adverse event; TEAE=treatment-emergent adverse event

^a TAEs reported in $\geq 1.0\%$ of subjects are included in the table in decreasing order of frequency

^b Drug-related TEAEs (according to investigator) reported in ≥ 2 subjects are included in the table.

^c SAEs reported by ≥ 2 subjects and AEs causing discontinuation in ≥ 2 subjects are included in the table. In addition, if the event was one of the TEAEs reported in $\geq 1.0\%$ of subjects, the data are included.

^d Includes subjects treated with 5% MTF, 2% MTS, and/or foam vehicle.

8.5 Post-Market Adverse Reactions

The following adverse drug reactions (ADRs) have been identified with the application of topical minoxidil during post-marketing use. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to the use of the drug. In Table 6 below, the ADRs are presented with ADR frequency categories estimated from spontaneous reporting rates according to the following convention:

Very common	≥1/10
Common	≥1/100 and < 1/10
Uncommon	≥1/1,000 and <1/100
Rare	≥1/10,000 and <1/1,000
Very rare	<1/10,000
Not known	(cannot be estimated from the available data)

Table 3: Adverse Drug Reactions Identified During Post-Marketing Experience with Topical Minoxidil by Frequency Category Estimated from Spontaneous Reporting Rates

System Organ Class	Adverse Event Preferred Term
Immune System Disorders	
Very rare	Angioedema (the manifestations of angioedema may include the following: Lip oedema, Oedema mouth, Oropharyngeal swelling, Pharyngeal oedema, and Tongue oedema)
Very rare	Hypersensitivity (the manifestations of hypersensitivity reactions may include the following: Face oedema, Generalised erythema, Pruritus generalised, and Throat tightness)
Very rare	Dermatitis contact
Psychiatric Disorders	
Very rare	Depressed mood
Nervous System Disorders	
Very rare	Dizziness
Eye Disorders	
Very rare	Eye irritation
Cardiac Disorders	
Very rare	Tachycardia
Very rare	Palpitations
Vascular Disorders	
Very rare	Hypotension
Gastrointestinal Disorders	
Very rare	Nausea
Very rare	Vomiting

System Organ Class	Adverse Event Preferred Term
Skin and Subcutaneous Tissue Disorders Very rare Very rare Very rare Very rare	Application site reaction (these sometimes involve nearby structures like the ears and face and typically consist of pruritus, irritation, pain, rash, oedema, dry skin, and erythema but can sometimes be more severe and include exfoliation, dermatitis, blistering, bleeding, and ulceration) Alopecia Hair colour changes Hair texture abnormal
General Disorders and Administration Site Conditions Very rare	Chest pain

9 DRUG INTERACTIONS

9.2 Drug Interactions Overview

There are currently no known drug interactions associated with concomitant use of systemic drugs and topical minoxidil. Absorption of topical minoxidil is controlled and rate-limited by the stratum corneum.

9.3 Drug-Behavioural Interactions

Interactions with lifestyle have not been established.

9.4 Drug-Drug Interactions

Topical drugs, e.g., tretinoin and anthralin, which alter the stratum corneum barrier, could result in increased absorption of topical minoxidil if applied concurrently. Betamethasone dipropionate has been shown to increase local tissue concentrations of Minoxidil and decreases systemic Minoxidil absorption in healthy volunteers. However, the effect of Betamethasone dipropionate on Minoxidil absorption with an inflamed scalp is not known. Although it has not been demonstrated clinically, there exists the theoretical possibility of absorbed Minoxidil potentiating orthostatic hypotension caused by peripheral vasodilators.

9.5 Drug-Food Interactions

Interactions with food have not been established.

9.6 Drug-Herb Interactions

Interactions with herbal products have not been established.

9.7 Drug-Laboratory Test Interactions

Interactions with laboratory tests have not been established.

10 CLINICAL PHARMACOLOGY

10.1 Mechanism of Action

Although the exact mechanism of action of minoxidil in the treatment of androgenetic alopecia is not known, there may be more than one mechanism by which minoxidil stimulates hair growth; they include:

- vasodilation of the micro circulation around the hair follicles which may stimulate hair growth
- direct stimulation of the hair follicle cells to enter into a proliferative phase; resting phase (telogen)
- follicles being stimulated to pass into growth phase (anagen) follicles.

10.2 Pharmacodynamics

The hemodynamic effects of minoxidil do not correlate directly with serum levels. There is a delay in onset relative to observable serum concentrations, peak hemodynamic effects lag one hour behind peak serum concentrations, and hemodynamic effects persist long after nearly all the minoxidil has disappeared from the circulation. It appears that minoxidil requires bioactivation before exerting its hemodynamic activity. The active metabolite is considered to be minoxidil sulphate. Sulfotransferase enzyme which converts minoxidil to minoxidil sulphate has been isolated from various human tissues including liver, platelets, scalp skin, hair follicles and epidermal keratinocytes. The effects of minoxidil on hair regrowth are possibly mediated by this active metabolite as well. In clinical studies, no correlation was established between serum or tissue minoxidil concentrations and hair regrowth.

In Vitro/in Vivo Studies

Exploratory in vivo and in vitro studies, designed to determine the mechanism by which minoxidil stimulates hair growth in patients with male pattern baldness have been completed, but have not been successful in definitely demonstrating the mechanism of action of minoxidil in stimulating hair growth. Studies have shown that there appears to be an immediate vasodilation of the micro circulation after topical application of minoxidil and that there is no significant alteration of the effects of androgens on scalp hair. These studies have also shown that cultured epidermal cells appear to be stimulated to divide under the influence of minoxidil and that in vitro cell cultures of lymphocytes are inhibited in their response to mitogens when minoxidil is present in culture. The overall significance of any of these studies is unknown.

In Vivo Studies

Results of two studies evaluating minoxidil tablets in doses up to 5 mg twice daily for up to 28 days in normotensive patients show that there were no clinically significant effects on blood pressure measurements or on pulse rate. In addition, there were no clinically significant changes in maximum heart rate response to standard treadmill test, pulse and blood pressure response to a dynamometer grip device, forearm blood flow, plasma renin levels or urine epinephrine and norepinephrine levels. No evidence of fluid retention was seen. The conclusion was made that low-to-moderate, short-term

doses of minoxidil tablets, in normotensive volunteers, do not lower blood pressure, and side effects commonly observed during minoxidil tablet therapy for hypertensive patients do not occur in normotensive subjects.

No clinically significant systemic effects were noted in a 16-week, placebo-controlled, randomized study of 98 treated hypertensive patients (involving B-blockers, diuretics) who were also treated with minoxidil topical solution 3%.

Untreated hypertensive patients were evaluated in an IV minoxidil study. The subjects achieved pharmacokinetic steady state within 6 hours after the start of infusion. The heart rate and diastolic blood pressure effects observed indicated that IV infusions of 1.37 mg and 3.43 mg of minoxidil did not result in clinically significant cardiovascular effects. The 6.86 mg dose, which resulted in a mean serum minoxidil concentration of 21.7 ng/mL, was the lowest dose clearly distinguishable from placebo, based on heart rate data.

Immune Function

A pilot study compared the immune status of 11 patients with male pattern baldness who were treated with topical minoxidil for 30 months, with the immune status of 12 untreated male control subjects. Peripheral leukocytes were examined for the presence of various cell subpopulations using monoclonal antibodies coupled with cytofluorometry and for blastogenic responses to phytohemagglutinin (PHA), concanavalin A (Con A), and pokeweed mitogen (PWM). The results of this study revealed no effect on helper T-cell, suppressor T-cell, B-cell, or natural killer cell numbers. In addition, no difference was observed in mitogenic responses of the minoxidil-treated patients (to any of the mitogens) as compared to responses of the control subjects.

Effect on Cardiac Function

An analysis of echocardiographic parameters such as left ventricular diameters in systole and diastole, septal and posterior wall thickness, cardiac output and cardiac index revealed no differences in patients exposed to 3% minoxidil solution for up to 5 years when compared to healthy patients that had not been exposed to 3% minoxidil during this time period.

10.3 Pharmacokinetics

Absorption

Absorption of topical minoxidil averages about 1.4% (range 0.3 to 4.5%) from normal intact scalp. Absorption is about 2% when applied topically to shaved scalps of hypertensive patients. Increasing the amount of drug applied or increasing the frequency of application of topical minoxidil also results in increased absorption. The use of minoxidil in conjunction with occlusion (plastic dressing) application to sunburn areas and increasing the surface area of application has minimal to no effect on the absorption of topical minoxidil.

Results of extensive pharmacokinetic studies indicate that the three major factors by which topical minoxidil absorption is increased are:

- increasing the magnitude of the dose applied
- increasing the frequency of dosing; and

- decreasing the barrier function of the stratum corneum.

The following table provides serum minoxidil concentrations measured in clinical efficacy studies.

Table 4: Serum concentrations of total minoxidil after the application of 1 mL of Men's Minoxidil twice daily

Serum minoxidil concentration (ng/mL)	Interval of exposure to Treatment					Summary		
	0-6 mths N	7-12 mths N	13-24 mths N	25-36 mths N	37-54 mths N	N	%	Cumulative %
<0.1	601	320	211	121	84	1337	31.2	31.2
0.1-2.0	1082	692	510	340	140	2764	64.5	95.6
2.1-5.0	65	38	28	17	7	155	3.6	99.3
5.1-8.0	6	3	2	4	0	15	0.3	99.6
8.1-12.0	4	3	2	0	0	9	0.2	99.8
12.1-15.0	1	0	0	0	0	1	0	99.8
15.1-18.0	1	0	0	0	0	1	0	99.9
18.1-21.0	0	1	0	0	1	2	0	99.9
> 21.0	1	3	0	0	0	4	0.1	100
Total	1761	1060	753	482	232	4288	100	100

Although the percutaneous drug absorption data are highly variable, the table shows that more than 99% of the values are below 5 ng/mL and less than 0.2% exceeds 12 ng/mL.

Absorption from the gastrointestinal tract following oral administration of minoxidil tablets is essentially complete (at least 95%).

In Vivo studies

Extent of Absorption

A three-way cross-over study in 14 male volunteers demonstrated that the extent of minoxidil absorption, by the topical route, is low; with bioavailability averaging 1.4% and 1.2%, for 2% and 3% topical solutions respectively, relative to oral doses of 2.5 mg minoxidil tablet.

The disappearance of minoxidil from the systemic circulation was found to be controlled by its rate of absorption, which is slow, and appears to occur by a zero-order process at steady state. Absorption of minoxidil from topically applied solution is greater in individuals with whom a simulated bald spot was generated by shaving (2.4% of applied dose) than in individuals who were naturally bald (1.4% of applied dose).

A four-way cross-over study in 23 male subjects demonstrated that the contact time of Men's Minoxidil Topical Solution affects absorption. Treatment involved dosing of 1mL q12h for 6 days applied to a constant surface area of the scalp. The scalp was washed one, two, four, and 11.5 hours

post dose. With increased contact time, absorption increased disproportionately. More than 50% of the minoxidil that is eventually absorbed is absorbed in the first hour post dose, and absorption is nearly complete after 4 hours.

The concomitant topical application of minoxidil with corticosteroids or tretinoin cream causes an increased absorption of minoxidil.

Effect of Surface Area

A four-way cross-over study documented that when 1 mL of 2% minoxidil solution was spread over surface areas ranging from 100 cm² to 200 cm², the amount of minoxidil absorbed was minimally affected. Less than a 20% increase in the amount absorbed was observed with a 100% increase in surface area.

Dose Proportionality

Results of a parallel design study of subjects applying 1 mL of a 0.01%, 0.1%, 1%, or 2% minoxidil solution twice daily to the scalp for two weeks indicate that absorption increases nearly linearly over the dose range studied. A cross-over study evaluating higher strength solutions demonstrated that the amount of minoxidil recovered in the urine increases less than in proportion to an increase in dose for the dose range evaluated. Subjects in this study had applied 1 mL of a 1%, 2%, or 5% solution to a constant 200 cm² surface area every 12 hours.

Frequency of Application

Percutaneous absorption is increased when the frequency exceeds twice daily dosing. Absorption for minoxidil that is applied to a healthy scalp does reach a threshold maximal level. It has been documented that the average amount of minoxidil recovered in the urine following 1 mL of 1% minoxidil solution administered every six hours was equivalent to that observed following 1 mL of 2% minoxidil administered every 12 hours.

Volume of Solution

A cross-over study evaluated the effect of the volume of application on the amount of minoxidil absorbed. This study documented that for a constant applied dose (10 mg) over a constant surface area, the volume applied has no influence on the amount of drug absorbed. Subjects received 1 mL of 1% minoxidil solution, 2 mL of 2% minoxidil solution, and 1/3 mL of 3% minoxidil solution.

Location of Application

No significant accumulation of minoxidil occurred as a result of applying up to four times the recommended dose of 3% minoxidil solution to the scalp or chest. In this parallel-design study, subjects received 1 mL of 3% minoxidil solution (30 mg) between two and eight times within a 12-hour interval for fourteen consecutive days. The results also demonstrated that there was no difference in absorption of minoxidil between the scalp and chest if applied less than eight times per day. Absorption of minoxidil appeared to be slightly greater in the scalp than in the chest at eight applications per day.

Overall, the results indicate that absorption of minoxidil solution was independent of the number of applications within a twelve-hour period for the doses administered in this study. This dosage range

(60 to 240 mg per day) was significantly greater than that used in previous studies which demonstrated a significant but less than proportional increase in the amount absorbed, following doses of 10 to 50 mg. The lack of an increase in serum or urine minoxidil levels with increased frequency of application seen in this study is probably the result of saturation of the stratum corneum with initial doses of minoxidil.

After application of minoxidil topical solution 2% q12h to the scalp, forearm, and upper back, it has been shown that systemic absorption is three-fold greater after application to the scalp compared to the forearm or back.

Animal Data

In Vivo studies

Results from a long-term dermal toxicity study in rats concluded that there was no apparent relationship between the nadir minoxidil levels and gross cardiac pathology. These nadir minoxidil levels in the rat were approximately 40 to 500 times higher than those documented in humans.

Results from a long-term dermal toxicity in rabbits concluded that increased heart and liver weights were drug-related; however, no concomitant histopathologic lesions were seen.

The following table provides a comparison of topically absorbed doses from a 2-year dermal carcinogenicity study in mouse and rat, compared to results obtained from humans using the recommended twice daily dose of Men's Minoxidil Topical Solution. The table demonstrates that on a mg/kg basis, the animals received higher doses than humans. In addition, the % minoxidil absorbed was much higher in the animals.

Both of these factors indicate that the systemic exposure to minoxidil in animals (in preclinical toxicity studies) is several hundred times greater than that associated with clinically recommended doses in man.

Table 5: Comparison of Minoxidil Absorption from different doses in Mouse and Rat to that from Men's Minoxidil Topical Solution BID in Humans

	Mouse			Rat			Man
Dose (mg/kg/day)	8	25	80	8	25	80	0.57
% absorbed	-	47.6	-	-	32.4	-	1.4
Available dose (mg/kg/day)	3.8	11.9	38.1	2.59	8.10	25.9	0.009
Ratio (animal/man)	422	1322	4233	288	900	2878	1.0

Following topical application, the urinary metabolite profiles in the rat corresponded closely to those observed after systemic administration, suggesting that metabolism was not altered by entry across the skin.

Characteristics of the topical absorption of ¹⁴C-labelled minoxidil differ appreciably in monkey scalp.

During the 10-16 days the monkeys were chaired, approximately 4% of the 1% solution and 1% of the 4% solution appeared in the urine. When returned to metabolism cages, a larger component of total urinary excretion occurred; urinary excretion did not follow first order kinetics. Total absorption in the monkeys was 17.4% of a 1% solution and 5.7% of a 4% solution.

Distribution:

Minoxidil does not bind to plasma proteins; its renal clearance corresponds to glomerular filtration rate, and it does not cross the blood brain barrier. Minoxidil and its metabolites are hemodialyzable, although this does not rapidly reverse its pharmacological effect.

Metabolism:

Approximately 90% of orally administered minoxidil is metabolized, predominantly by conjugation with glucuronic acid at the N-oxide position in the pyrimidine ring and by conversion to more polar products.

In Vitro Studies

The transdermal metabolism of ¹⁴C-minoxidil in fresh human skin in an in-vitro diffusion system was studied. The dermal metabolism of minoxidil in human skin under these in-vitro conditions was minimal at 4.8 to 6.0% of the applied dose.

Elimination

Serum minoxidil levels and systemic effects resulting from administration of topical minoxidil are governed by the drug's absorption rate through the skin. Following cessation of topical dosing of minoxidil, approximately 95% of systemically absorbed drug is eliminated within four days. Minoxidil and its metabolites are excreted principally in the urine.

11 STORAGE, STABILITY AND DISPOSAL

Women's GLN-MINOXIDIL should be stored at controlled room temperature range of 15-30 °C. Do not puncture or incinerate container. Do not expose to heat or temperature above 50°C. Store in upright position.

PART II: SCIENTIFIC INFORMATION


13 PHARMACEUTICAL INFORMATION

Drug Substance

Proper name: minoxidil

Chemical name: 2,4,-Pyrimidinediamine,6-(1-piperidinyl)-,3-oxide

Molecular formula and molecular mass: C₉H₁₅N₅O; 209.25



Structural formula:

Physicochemical properties: A white or off-white, crystalline solid that is slightly soluble in water, soluble in propylene glycol and in alcohol, sparingly soluble in methanol, and practically insoluble in acetone, chloroform, ethyl acetate and in hexane. It melts in the approximate range of 248°C.

14 CLINICAL TRIALS

14.1 Clinical Trials by Indication

Women's MINOXIDIL

Men's minoxidil applied twice daily (BID) (40 mg daily minoxidil dose) was compared to Women's minoxidil FOAM 5% applied once daily (OD) (50 mg daily minoxidil dose) in a multi-centre trial (MINALO3004) in which women aged 18 years and older with female pattern hair loss were enrolled. In both arms 161 women were entered into the study of which 137 women completed using minoxidil topical 2% solution (MTS 2%) and 130 completed the study using minoxidil 5% foam (MTF 5%). The primary endpoint of the study was change from baseline in total area hair count (TAHC) as measured by macrophotography at week 24. The secondary endpoint was change from baseline in TAHC as measured by macrophotography at week 12.

Table 6: Summary Demographic Characteristics of Women's MTF 5% Study Subjects (MINALO3004)

<u>Treatment</u>	<u>MTS 2% Twice Daily</u>	<u>MTF 5% Once Daily</u>
Mean age (SD) (years)	53.0 (12.88)	53.1 (13.09)
Minimum, Maximum	18-86	18-86

<u>Treatment</u>	<u>MTS 2% Twice Daily</u>	<u>MTF 5% Once Daily</u>
Race, n (%)		
White	149 (92.5)	141 (87.6)
Non-White*	12 (7.5)	20 (12.4)
Menopausal status, n (%)		
Pre	66 (41)	67 (41.6)
Post	95 (59)	94 (58.4)

* Non-White includes Black or African American, Asian, Native Hawaiian or other Pacific Islander, American Indian or Alaska Native and Other.

A comparative 24-week study in women (MINALO3004) between 2% MTS and 5% MTF is described above. Also, Women's MINOXIDIL FOAM 5% (5% MTF) was studied in a randomized, double-blind vehicle- controlled, multi-centre, parallel-design trial in women 18 years of age and older (MINALO3005). Subjects were randomized in a ratio of 1:1 to apply one-half capful (1 gram) of 5% MTF once daily or foam vehicle once daily for 24 weeks. Primary efficacy was assessed by the change from baseline TAHC as measured by macrophotography at baseline and week 24, and subject assessment of scalp coverage from global photographs, as measured by the change from baseline at week 24 on a 7-point scale. Secondary efficacy was evaluated by the change from baseline in TAHC, as measured by macrophotography at baseline and week 12. Additional analyses included an Expert Panel Review of hair regrowth based on global photographs, as measured as the change from baseline at week 24 on a 7-point scale, and the change from baseline in Total Unit Area Density (TUAD)

Table 7: Summary Demographic Characteristics of Study Subjects (MINALO3005)

<u>Treatment</u>	<u>Foam Vehicle OD</u>	<u>MTF 5% OD</u>
Mean age (SD) (years)	56.3 (11.68)	55.0 (12.12)
Age: Min, Max (years)	18-86	18-86
Race, n (%)		
White	140 (69.7)	145 (71.8)
Black/African American	55 (27.4)	50 (24.8)
Other*	6 (2.9)	6 (3.4)
Menopausal status, n (%)		
Pre	61 (30.3)	71 (35.0)
Post	140 (69.7)	132 (65.0)

* Other includes Asian, Native Hawaiian or other Pacific Islander, American Indian or Alaska Native and non-specified.

14.2 Study Results

Women's MINOXIDIL (Minoxidil 50mg/g [5% w/w])

The following tables provide comparative data for parameters that were evaluated in the MINALO3004 (2% MTS and 5% MTF) and MINALO3005 (MTF vehicle and 5% MTF) studies.

Table 8: Efficacy Assessments at Week 24 from MINALO3004 and MINALO3005 Studies

Assessment at 24 weeks	MINALO3004		MINALO3005	
	2% MTS BID N=161	5% MTF OD N=161	Foam Vehicle OD N=201	5% MTF OD N=203
Adjusted Mean (SE) change from baseline for TAHC/cm ²	23.8 (24.7)	23.7 (22.9)	4.0 (16.2)	13.5 (22.3)
p-value (95% CI)		0.9170 (-6.0,5.4)		<0.0001 (5.0, 13.1)
Adjusted Mean (SE) change from baseline TUAD (μM)/cm ²	1948.2 (149.3)	1660 (149.0)	316.5 (107.4)	960.5 (109.6)
p-value (95% CI)		0.1660 (-696.9, 120.4)		<0.0001 (345.5, 942.5)
Adjusted Mean (SE) change in Expert Panel Review scale	0.60 (0.07)	0.66 (0.07)	0.11 (0.05)	0.47 (0.05)
p-value (95% CI)		0.4925 (-0.12, 0.24)		<0.0001 (0.22, 0.50)

MTS = Minoxidil Topical Solution; MTF = Minoxidil Topical Foam; BID = twice daily; TAHC/cm² = Total Area Hair Count per square centimeter of scalp; TUAD/cm² = Total Unit Area Density per square centimeter of scalp; Expert Panel Review scale = -3 to +3 (7 point) scale

Table 9: Efficacy Assessments at Week 24 Based on Pooled Data from MINALO3004 and MINALO3005 Studies

Assessment at 24 weeks	Foam Vehicle OD N=201	2% MTS BID N=161	5% MTF OD N=364
Mean (S.E.) change from baseline in TAHC per cm ²	4.0 (16.2)	23.8 (24.7)	18.2 (23.1)
% Subjects with change from baseline in TAHC per cm ² ≥ 0	63	87.7	85.0

Assessment at 24 weeks	Foam Vehicle OD N=201	2% MTS BID N=161	5% MTF OD N=364
Mean (S.E.) change from baseline in TUAD (μM) per cm^2	274.6 (1282.9)	1890.1 (1796.6)	1265.1 (1652.0)
% Subjects with increase from baseline in TUAD (μM) per cm^2	67.3	89.1	82.3
% Subject self assessment of at least mild scalp coverage	42.1	-	55.5
% Subject self assessment of at least moderate scalp coverage	21.9	-	38.3
Mean (S.D.) Expert Panel Review increase in scale (-3 to +3)	+0.09 (0.62)	+0.60 (0.78)	+0.54 (0.77)
% Subjects evaluated by Expert Panel Review to have at least mild improvement in scalp coverage	17.6	49.7	43.5
% Subjects evaluated by Expert Panel Review to have at least moderate improvement in scalp coverage	2.2	12.6	11.6

MTS = Minoxidil Topical Solution; MTF = Minoxidil Topical Foam; OD = daily; BID= twice daily TAHC = Total Area Hair Count; TUAD = Total Unit Area Density

14.3 Comparative Bioavailability Studies

Women's GLN-MINOXIDIL (Minoxidil Foam, Aerosol Foam 50 mg/g (5% w/w)) has satisfied the criteria for a biowaiver in comparison to Women's ROGAINE® FOAM 5% (Minoxidil Foam 50 mg/g (5% w/w)) (Johnson & Johnson Inc).

15 MICROBIOLOGY

No microbiological information is required for this drug product.

16 NON-CLINICAL TOXICOLOGY

General Toxicology:

Acute Toxicity

Table 10: LD50 (mg/kg) in Mouse and Rat by Route of Administration

SPECIES	ROUTE	LD50(mg/kg)
Mouse	Oral	2457
	Intraperitoneal	1001
	Intravenous	51
Rat	Oral	1321
	Intraperitoneal	759
	Intravenous	49
Rat	Cutaneous	≥2007

Signs of Toxicity

CNS depression and acute pulmonary congestion.

Concomitant therapy with either prednisone and anti-thymocyte globulin, hydrochlorothiazide and propranolol, or digoxin and furosemide did not appreciably alter the LD₅₀ for minoxidil. Acute toxicity evaluations of cutaneous administration of minoxidil did not result in mortalities at 999 and 1998 mg/kg, therefore the LD₅₀ was not determined.

Repeat Dose Toxicity

Oral Studies

3-Day Studies (Rat, Dog)

Minoxidil was administered orally to rats and dogs at daily doses up to 100 and 10 mg/kg/day respectively for 3 days. In rats, a dose related slight increase in the number of mitoses in hepatocytes was seen. In beagle dogs, epicardial and myocardial cellular infiltrations, hypertrophy and hyperplasia of the mesothelial cells, small focal hemorrhages, and myocardial atrial lesions were observed at 1.0 and 10 mg/kg doses. These findings were more frequent and severe at the higher dose. In mongrel dogs, there were minimal to mild subepicardial hemorrhages present in the right atrium and/or right auricle which may represent the early stages of right atrial lesions as seen in the longer-term studies.

1-Month Studies (Monkey, Dog, Minipig, Rat)

Minoxidil was administered orally to monkeys at 20 mg/kg/day; to dogs at 0.5 and 1 mg/kg/day, and at 20 and 100 mg/kg/day; to minipigs at 20 mg/kg/day; and to rats at 300 mg/kg/day. Grossly observed cardiac hypertrophy was reported in the monkey study (the 4-OH metabolite of minoxidil at the same

dose showed no effect). In dogs, lesions of the right atrium and/or auricle were seen at all doses. Local myocardial cell atrophy and/or degeneration were reported at doses as low as 1 mg/kg/day. The 20 mg/kg dose produced degenerative right auricular heart lesions as did the 4-OH metabolite of minoxidil. The high dose resulted in the death of all dogs probably due to profound alteration in electrolyte balance. In the minipig study blood pressure was depressed, heart rate elevated, and total body water and exchangeable sodium were increased. Cardiac lesions due to minoxidil were not seen. In rats, repression of body weight gain, decreased food consumption, reduced erythrocyte levels increased liver and heart weights, indications of cardiac hypertrophy and electrolyte imbalance were observed.

1-Year Studies (Rat, Monkey, Dog)

Minoxidil was administered orally to rats at 10, 30 and 100 mg/kg/day, monkeys at 3.5, 7 and 14 mg/kg/day and dogs at 3, 10 and 30 mg/kg/day. In rats, repression in body weight gain occurred and a dose related increase in liver, kidney, adrenal and heart weights was seen. One high dose female monkey with chronic glomerulonephritis died from cardiac failure and minoxidil probably contributed because of its salt and water retaining action. In the dog study, degenerative right auricular heart lesions were found at all dose levels. Evidence of chronic electrolyte disturbance was noted in dogs at the highest dose.

22-Month Study (Rat)

Minoxidil was administered orally to rats at 3, 10 and 30 mg/kg/day. Increased heart weights were observed at the highest dose. No carcinogenic potential was apparent.

Topical Application Studies

91 - Day (Beagle Dog)

Minoxidil was administered topically to male and female dogs at doses of 0.6, 1.2 and 4.8 mg/kg/day. Hemorrhagic atrial lesions were seen in the right atrium of the heart at all doses over a treatment period of 91 days. Cardiomyopathy and epicarditis of the atrial wall, increased organ weights and decreased inorganic phosphorous levels were reported. The hemorrhagic right atrial lesions reported in this study have not been observed in seven other species (including man) following minoxidil administration.

13-Day (Beagle Dog)

¹⁴C-minoxidil was administered topically and orally to female dogs at a dose of 4.8 mg/kg/day for 3 days followed by non-radioactive minoxidil for 10 days. Hemorrhagic right atrial lesions, papillary muscle necrosis/paleness and epicarditis of the right atrium were evident in topically and orally treated groups. Since the percutaneous absorption of minoxidil in dogs is 39% and 2 - 4% in man, the potential of the development of right atrial lesions is not applicable to man.

Other Topical Application Studies

Rat

Notable toxicity was seen only in topical studies done in rats. When Men's minoxidil was administered

topically to rats, approximately 32% of the dose was absorbed. Therefore, 1 mL of minoxidil 1% topical solution applied twice daily (20 mg/day), represents 2476 times the human topical dose on the basis of a 250 g rat, a 50 kg human, 32% absorption in rats and an average of 1.4% absorption in man. One mL of minoxidil 5% topical solution applied twice daily (100 mg/day) represents 12381 times the human topical dose.

In the 94-day dermal rat study (1 mL/day), signs of toxicity were mainly noted in the 6% minoxidil solution group (60 mg/day). The toxicity consisted of dose-related increased nasal and ocular porphyrins; area of soreness in the treatment area (also noted in one control rat); and fecal stains in a few rats of the 6% group. Females had decreased body weight gains, and the following organ weight changes were seen: increased spleen weights for both sexes at all dose levels; increased heart weights for males at all dose levels and for females in the 1% group (10 mg/day); and increased liver weights for males in the 3% (30 mg/day) and 6% (60 mg/day) groups. There were, however, no drug-related lesions involving the skin or internal organs.

A one-year dermal toxicity study in male and female rats at doses of 1 mL b.i.d. of 1%, 3% and 5% minoxidil resulted in decreased body weight gains, increased urinary protein, slight enlargement and/or dilatation of the heart, increased organ weights and histopathologic findings such as cardiac and hepatocellular hypertrophy, myocardial degeneration and increased nephritis. Most of the effects were evident in the 3% (60 mg/kg/day) and the 5% (100 mg/kg/day) groups.

The decreased body weights in females, increased organ weights and histopathologic findings are associated with high systemic doses of minoxidil and, therefore, do not constitute new findings. The systemic doses reached in this study are approximately 2,000 to 12,000 times the human topical dose. The minimal irritation and thickening of the skin were not considered drug-related or of consequence.

Rabbit

On a volume basis (4 mL/day), the dose levels tested in rabbits represent one to five times the human dose. However, on the basis of a 2.5-kg rabbit and a 50-kg man, the dose levels represent 20 to 100 times the human topical dose of Men's Minoxidil Topical Solution. The absorption of topical applications of Men's Minoxidil Topical Solution has not been investigated in the rabbit.

In the 21-day dermal study in the rabbit, drug-related clinical signs were absent. Relative and/or absolute heart weights were significantly increased in the males which received the 3% and 5% minoxidil topical solutions, as compared to the controls. No histopathologic lesions were seen.

A one-year dermal toxicity study in male and female rabbits at doses of 2 mL b.i.d. of 1%, 3% and 5% minoxidil resulted in dilated ventricles of the heart, increased organ weights, and slight to moderate irritation. Except for site irritation, none of these effects were evident in the 1% group.

Eye Irritation Studies

A single 0.1 mL dose of a 2% minoxidil solution was instilled into the conjunctival sac of the right eye of New Zealand white rabbits. The left eye served as a control. It was concluded that minoxidil topical solution 2% is an irritant.

A single 100 mg dose of 2% minoxidil gel was instilled into the conjunctival sac of the right eye of

three male and three female New Zealand White rabbits. The left eye was untreated and served as control. At one-hour post-instillation, all six treated eyes exhibited slight-to-moderate conjunctival irritation, as indicated by slight redness, slight-to-moderate swelling, and discharge. By 24 hours, the eye irritation remained at approximately the same level for five rabbits, while the irritation in the eye of one female rabbit deteriorated to include slight corneal opacity and iridal capillary injection. However, the irritation gradually subsided by 96 hours post-dosing. By day 7 post-treatment, all the treated eyes appeared normal.

A single 100 mg dose of 3% minoxidil gel was instilled into the conjunctival sac of the right eye of three male and three female New Zealand White rabbits. The left eye was untreated and served as control. Slight-to-moderate conjunctival redness and swelling, and slight-to-severe discharge were observed in all treated eyes from 1-96 hours post-dosing.

In addition, the treated eyes of two males and one female also exhibited slight corneal opacity and corneal epithelial exfoliation for 1-24 hours post-dosing. However, the treated eyes of all six rabbits appeared normal by day 7 post-treatment.

Gel formulations of minoxidil used in the eye irritation studies; contain the same excipients that are present in Men's Minoxidil Topical Solution, with the exception that a gelling agent and a stabilizer are present in the gel formulation. The alcohol content in the gel formulations is lower than that of the topical solution. Since alcohol is a known eye irritant, it can be concluded that Men's Minoxidil Topical Solution is also an eye irritant.

Phototoxic/Photoallergic Study

Guinea Pig

Minoxidil topical solution 2% in guinea pigs caused no reaction in a phototoxicity/photoallergic study.

Carcinogenicity: Two-year carcinogenicity studies of minoxidil have been conducted by the dermal and oral (dietary) routes of administration in mice and rats.

In the two-year dermal study in mice, an increased incidence of mammary adenomas and adenocarcinomas in the females at all dose levels (8, 25 and 80 mg/kg/day) was attributed to increased prolactin activity. Mechanistic studies in female mice objectively demonstrated an increased prolactin secretion in mice treated topically with minoxidil for 90 days.

Other hormonal changes, including decreased LH, FSH, and estrogen, which are consistent with hyperprolactinemia, were also observed in these studies. In addition, histological changes consistent with a hyperprolactinemic state were observed in the 90 day and 2-year studies. Hyperprolactinemia is a well-known mechanism in the enhancement of mouse mammary tumors but has not been associated with mammary tumorigenesis in women. Additionally, topical minoxidil has not been shown to cause hyperprolactinemia in women on clinical trials. Absorption of minoxidil through rodent skin is greater than would be experienced by patients treated topically with minoxidil for hair loss. In a dietary study of minoxidil in mice for up to 2 years, malignant lymphomas were seen earlier in females which failed to survive for 2 years in the high dose (63 mg/kg/day) compared to controls. However, this finding was not observed in 2-year topical studies and higher systemic studies. In the 2-year dermal study in mice there was an increased incidence of hepatic nodules in males (63 mg/kg/day); however, there was no effect of dietary minoxidil on malignant lymphomas.

In the two-year dermal study in rats there were significant increases in incidence of pheochromocytomas in males and females and preputial gland adenomas in males. Mechanistic studies in male rats objectively demonstrated an increased prolactin secretion in rats treated topically with minoxidil for 90 days.

Other hormonal changes consistent with hyperprolactinemia in males were also observed in these studies. The increased incidence of preputial gland adenomas observed in male rats is consistent with the increased prolactin levels observed in this species and sex.

Changes in incidence of neoplasms found to be increased in the dermal or oral carcinogenicity studies were typical of those expected in rodents treated with other hypotensive agents (adrenal pheochromocytomas in rats), treatment-related hormonal alterations (mammary carcinomas in female mice; preputial gland adenomas in male rats) or representative of normal variations within the range of historical incidence for rodent neoplasms (malignant lymphomas, liver nodules/adenomas in mice). Based on differences in absorption of minoxidil and mechanisms of tumorigenesis in these rodent species, none of these changes were considered to be relevant to the safety of patients treated topically with minoxidil for hair loss.

There was no evidence of epithelial hyperplasia or tumorigenesis at the sites of topical application of minoxidil in either species in the 2-year dermal carcinogenesis studies. No evidence of carcinogenicity was detected in rats or rabbits treated topically with minoxidil for one year. Topical minoxidil (2% and 5%) did not significantly ($p < 0.05$) reduce the latency period of UV light-initiated skin tumors in hairless mice, as compared to controls, in a 12-month photocarcinogenicity study.

Positive carcinogenicity findings which occurred in the topical rodent studies did not occur in the oral studies. A comparative bioavailability study using the identical routes and methods of administration used in the topical and oral (drug-in-diet) studies indicated that a 45-fold C_{max} and a 3-fold C_{av} higher systemic exposure to minoxidil occurs after topical vs oral treatment in rodents. Additionally, a study which compared the route dependent absorption, excretion and metabolism of minoxidil- $[^{14}C]$ after topical and oral administration in the female mouse and rat suggested intrinsically greater percutaneous absorption of the topically applied minoxidil- $[^{14}C]$ in the mouse relative to that in the rat.

Genotoxicity: Minoxidil was not genotoxic in the Salmonella (Ames) test (TA-98-100, TA-98-1535, TA-98-1537, TA-98-1538), the DNA damage alkaline elution assay, the *in vitro* rat hepatocyte unscheduled DNA synthesis (UDS) assay, the rat bone marrow micronucleus assay, or the mouse bone marrow micronucleus assay. An equivocal result was recorded in an *in vitro* cytogenetic assay using Chinese hamster ovary cells at long exposure times, but a similar assay using human lymphocytes was negative.

Reproductive and Developmental Toxicology: Male rats received minoxidil in oral doses of 3 or 10 mg/kg/day for 60 days prior to and during the 14-day breeding period. Female rats received the same dose for 14 days prior to and during breeding, and throughout gestation. A reduction in conception rate was observed. No increase in the incidence of fetal resorption in treated dams was seen. The average number of live pups per litter was significantly decreased in both treatment groups, but live pups from treated dams were significantly heavier than live pups from control dams.

Minoxidil, when given orally to pregnant rats and rabbits on gestation days 6 through 15 and 18 respectively, at dose levels of 3 and 10 mg/kg/day showed no teratogenic effect. Increased fetal

resorption occurred in rabbits. The same dose administered to rats from the 15th day of gestation until pups were weaned at 21 days showed no effect of treatment on various parameters related to gestation, parturition and lactation.

When a minoxidil suspension was given subcutaneously to pregnant rats in doses of 0, 1, 11, and 120 mg/kg, no teratogenic changes were found in the fetuses from the rats dosed at 0, 1 and 11 mg/kg of minoxidil. Increased fetal mortality, still birth, external malformations and skeletal anomalies and variations were observed at 120 mg/kg. This dose also caused decreased maternal weight gain and food consumption and thus the fetal effects noted could have resulted from maternal toxicity.

Minoxidil administered subcutaneously to pregnant rats at 80 mg/kg/day was maternally toxic (manifested by general malaise and weight loss) but not teratogenic. This is about 2000 times the maximum daily systemic human exposure after topical administration.

Higher doses (120 and 160 mg/kg/day) produced some fetal malformations. The no adverse effect level (NOAEL) for maternal toxicity was 40 mg/kg/day while the NOAEL for developmental toxicity was 80 mg/kg/day.

Special Toxicology:

Cardiovascular Mechanistic Studies (dog): The mechanisms of the various cardiovascular lesions induced by minoxidil are considered to be related to the exaggerated pharmacologic/hemodynamic effects of the drug rather than to a direct toxicity of the drug. The mechanism of cardiovascular toxicity of minoxidil (an ATP-sensitive potassium channel opener) was studied by blocking its pharmacologic effects with glyburide (an ATP-sensitive potassium channel antagonist) in beagle dogs that were treated orally for two days either with minoxidil alone or in combination with glyburide. Glyburide did not influence the pharmacokinetics of minoxidil but prevented or markedly attenuated the minoxidil-induced carotid pulsation, hypotension, and tachycardia. None of the cardiovascular lesions (right atrial hemorrhagic lesions, subendocardial necrosis, or coronary arteritis) occurred in dogs whose minoxidil-induced hemodynamic effects were effectively blocked by glyburide. These findings led to the conclusion that the cardiovascular toxicity of minoxidil in dogs is related to its exaggerated pharmacologic (hemodynamic) effects rather than by a direct toxic effect of minoxidil on the heart.

The threshold serum concentrations of minoxidil for hemodynamic effects and cardiovascular lesions were determined in dogs administered minoxidil by continuous infusion at doses ranging from 0.05 to 4.32 mg/kg/day for three days. Classic minoxidil-induced cardiovascular lesions were observed after profound hemodynamic changes occurred at doses of 0.43 mg/kg/day or higher. The absence of these lesions at 0.14 mg/kg/day, in which there was tachycardia without significant hypotension, indicated that hypotension may be important for the development of cardiovascular lesions.

The threshold dose/serum concentrations of minoxidil for hemodynamic effects (heart rate) and cardiovascular toxicity were approximately 0.05 mg/kg/day (2.0 ng/mL) and 0.14 mg/kg/day (7.96 ng/mL), respectively.

Since dogs are particularly sensitive to the cardiac effects of minoxidil and other vasodilating agents, they are not considered to accurately predict human risk for these compounds. Human exposure would be about 0.028 mg/kg/day (assuming a 60 kg individual using twice daily applications of 1 mL of 5% minoxidil topical solution and a mean level of minoxidil absorption in humans of 1.7%), which provides a difference in exposure between humans and dogs of 8-fold or more for a 5% solution.

There is no clinical or autopsy evidence that orally administered minoxidil causes similar cardiac toxicity in humans.

Drug Interaction Studies: There was no evidence of alteration in toxicity when minoxidil was given concomitantly with (a) hydrochlorothiazide and propranolol in rats and monkeys for up to 1 month, and (b) furosemide and digoxin in rats for 1 month. Hydrochlorothiazide partially reduced increases in heart weight and total body exchangeable sodium produced by minoxidil in a 1-month monkey study.

Longer term treatment in rats, dogs and monkeys showed cardiac hypertrophy and cardiac dilation (in rats). Hydrochlorothiazide partly reversed the increased heart weight in monkeys.

17 SUPPORTING PRODUCT MONOGRAPHS

1. Women's ROGAINE® FOAM 5% (Minoxidil Foam 50 mg/g (5%w/w)), Submission Control # 251296, Product Monograph, Johnson & Johnson Inc. (JAN 20, 2022)

PATIENT MEDICATION INFORMATION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

Women's GLN-MINOXIDIL

Minoxidil Foam

Read this carefully before you start taking **Women's GLN-MINOXIDIL** and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about **Women's GLN-MINOXIDIL**.

What is Women's GLN-MINOXIDIL used for?

- Women's GLN-MINOXIDIL is used for the treatment of female pattern hair loss/thinning in women aged 18 years of age and older. It prevents further hair loss and helps hair re-growth.

How does Women's GLN-MINOXIDIL work?

Women's GLN-MINOXIDIL contains minoxidil, which is thought to work by aiding the blood flow to hair follicles on your scalp and thereby helping hair re-growth. Initial hair re-growth may look soft, downy ("vellus" hair), and may be barely visible. After further treatment, hair re-growth may change and become the same colour and thickness as the rest of the hair.

Women's GLN-MINOXIDIL is more effective if you are experiencing gradually thinning hair on the top of your scalp (as shown in the image below).



Gradual hair loss/thinning on the top of the scalp

Female Pattern Baldness or Hereditary Hair Loss is recognizable because:

- Of the pattern of hair loss (see diagrams on the previous page).
- Hair loss starts gradually and progresses.
- other family members have experienced it.
- No other symptoms are present with your hair loss.



Non-female pattern hair loss

Do not use if you have patchy hair loss as shown in the picture to the left.

Since normal hair growth takes time, hair regrowth with Women's GLN-MINOXIDIL also takes time. Results may be seen as early as 3 months, but, for some women, it may take at least 6 months. If you do not see results in 6 months, stop using the product and see your doctor.

The amount of hair regrowth is different for each person. Not everyone will respond to Women's GLN-MINOXIDIL. The response to this medicine cannot be predicted. No one will be able to grow back all of her hair.

You may respond better if you have been losing your hair for a shorter period of time (less than 10 years).

What are the ingredients in Women's GLN-MINOXIDIL?

Medicinal ingredients: minoxidil

Non-medicinal ingredients: Anhydrous Citric Acid, Butylated Hydroxyl Toluene, Cetyl Alcohol, Dehydrated Alcohol, Glycerin, Hydrocarbon Propellant (propane, isobutane, n-butane), L-Lactic Acid, Purified Water, Polysorbate 60, and Stearyl Alcohol.

Women's GLN-MINOXIDIL comes in the following dosage form:

Foam that contains 50 mg minoxidil per gram (5% w/w) and is delivered from a pressurized container

Do not use Women's GLN-MINOXIDIL if:

- you are less than 18 years of age (do not use on babies or children)
- you are pregnant, or breastfeeding
- you are allergic to minoxidil or to any ingredients in Women's GLN-MINOXIDIL
- you have treated or untreated high blood pressure
- you have no family history of hair loss
- you do not know the reason for your hair loss
- you have hair thinning/loss that is due to childbirth, is patchy, or is sudden and unexpected

- your degree of hair loss is greater than that shown in the ‘How does Women’s GLN-MINOXIDIL work?’ section, as this product may not work for you
- you have any condition that affects your scalp such as redness, swelling, irritation, pain on touching, sunburn, or psoriasis
- you have a shaved scalp or broken skin on the scalp
- you are treated with any kind of dressing or bandage (occlusive dressing) or other topical medication (e.g., anthralin, tretinoin or corticosteroids) on your scalp for any skin scalp problems
- you have temporary hair loss as a result of taking certain medications (cancer chemotherapy), recently stopped taking birth control pills, low thyroid states (hypothyroidism), or having certain diseases that cause scarring of the scalp or certain serious nutritional problems (very low body iron, excessive vitamin A intake), as well as certain grooming methods (cornrowing, tight ponytails, use of haircare products that cause scarring or deep burns).
- you have secondary syphilis

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take Women’s GLN-MINOXIDIL. Talk about any health conditions or problems you may have, including if you:

- have high or low blood pressure or heart disease or irregular heartbeat (arrhythmia)
- are under other treatment for any scalp conditions

Other warnings you should know about:

- Apply Women’s GLN-MINOXIDIL only on the scalp.
- Avoid contact with eyes as Women’s GLN-MINOXIDIL contains alcohol, which would cause burning or irritation of the eyes or sensitive skin areas. If contact occurs, rinse thoroughly with large amounts of cool tap water. Stop use and speak to your doctor if irritation lasts for a long time.
- Women’s GLN-MINOXIDIL may cause local skin reactions (contact dermatitis), irritation to the eyes or mucous membranes.
- May change colour/texture of hair
- Avoid inhalation of the spray
- In rare cases, Women’s GLN-MINOXIDIL may cause low blood pressure, salt and water retention that lead to chest pain (angina), rapid heartbeat (tachycardia), swollen hands and feet
- Shedding of hair may occur within two to six weeks after using the product; this is not uncommon and is temporary. If shedding persists for more than two weeks, stop applying Women’s GLN-MINOXIDIL and consult your doctor to determine the cause for the hair loss.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

The following may interact with Women’s GLN-MINOXIDIL:

- Anthralin – used to treat psoriasis
- Tretinoin – used to treat acne or other skin conditions

- Women's GLN-MINOXIDIL (Minoxidil) also may increase the effect of hydralazine (drug to treat high blood pressure).

How to take Women's GLN-MINOXIDIL:

- Women's GLN-MINOXIDIL is for topical and external use only. It should only be applied directly to the scalp area. Make sure your hair and scalp are completely dry before applying the foam.

Pre-Application:

- Shampooing is not required before applying Women's GLN-MINOXIDIL. However, if you wash your scalp before applying, use a mild shampoo. Dry hair and scalp before application.
- Do not apply to areas of the body other than the scalp.
- Do not apply to a sunburned or irritated, broken, or shaved scalp.
- For Women's GLN-MINOXIDIL to work best, you should allow it to remain on the scalp for at least 4 hours.

Application:



1. PREP HANDS WITH COLD WATER

Rinse your fingers in cold water and dry them. **Note:** foam will melt on contact with warm surfaces.



2. OPEN THE CAP

Be sure to align arrow on the cap with arrow on blue ring. Tilt cap back and pull off.



3. HOLD CAN STRAIGHT UPSIDE DOWN AND DISPENSE ONTO A COLD SURFACE

If you hold the can at an angle, foam may not dispense properly. Press nozzle to dispense half a capful of foam onto a **cold** surface (e.g. dish, or cold hands).



4. APPLY TO SCALP, NOT HAIR

Part your hair to expose hair loss area. Massage foam into **scalp**, not hair. **Repeat** until all hair loss areas have been covered.





5. CLOSE CAP AND WASH HANDS

Snap cap back into place. Be sure arrows do not line up, so cap remains child resistant. Wash hands and any surface thoroughly after use.

After Application:

- Do not dry the foam with a hair dryer.
- If you are planning to be in the sun after applying Women's GLN-MINOXIDIL, use headwear. Do not use sunscreens or sun-blocking agents on the scalp.
- Avoid swimming, showering or physical activity involving excessive sweating or wetting in rain for at least 4 hours after application.
- If applying at night, allow foam to naturally and completely dry before going to bed.

Hair Styling:

- To minimize breakage of existing hair, the scalp should be massaged gently. Comb hair with a widely spaced, round tooth comb to avoid excessive pulling.

For your hair care routine with other products please note below how Women's GLN-MINOXIDIL should be applied.

Sprays, mousses, conditioners, gels

- You may use hair sprays, mousses, conditioners, gels, etc. However, you should apply Women's GLN-MINOXIDIL first and wait for it to dry before applying your styling aids.

Hair colouring, perming or relaxer agents

- It is not known if hair colouring, perming or relaxer agents change the effect of Women's GLN-MINOXIDIL. However, to avoid possible scalp irritation, you should make sure all of the foam has been washed off the hair and scalp before using these products. Do not apply Women's GLN-MINOXIDIL for 24 hours after using a chemical treatment (perm, colour) to make sure your scalp has not been irritated by the perm or colour treatment. If irritation occurs from chemical treatment, discontinue use of Women's GLN-MINOXIDIL until irritation is gone. There is no need to use more Women's GLN-MINOXIDIL to make up for missed applications.

Usual dose:

Half (½) a capful of foam applied once daily to the entire affected area

- To be effective, it is important to apply the product **DIRECTLY TO YOUR SCALP** and **NOT TO YOUR HAIR** so that it can easily get to your hair follicles to help regrow your hair
- If applying at night, allow foam to naturally and completely dry before going to bed.

Do not exceed one-half (½) capful in a day. Exceeding the recommended dosage may cause increased side effects and will not cause the product to work better or faster.

One can of Women's GLN-MINOXIDIL should last about 60 days (two months), if applied once a day according to directions.

If you do not see any results after 6 months, stop using Women's GLN-MINOXIDIL and seek the advice of your physician to determine if you should resume using the product.

Overdose:

If you think you, or a person you are caring for, have taken too much Women's GLN-MINOXIDIL, contact a healthcare professional, hospital emergency department, regional poison control centre or Health Canada's toll-free number, 1-844 POISON-X (1-844-764-7669) immediately, even if there are no signs or symptoms.

Missed Dose:

- If you miss one or two applications, skip the missed dose(s) and continue your regular dosing schedule. Do not apply a double dose to make up for a missed one.

What are possible side effects from using Women's GLN-MINOXIDIL?

These are not all the possible side effects you may have when taking Women's GLN-MINOXIDIL. If you experience any side effects not listed here, tell your healthcare professional.

If you experience any of the following, stop using the medicine and tell your doctor

- Faintness or dizziness – if affected do not drive or operate machinery
- Sudden unexplained weight gain
- Unwanted facial hair growth
- Swollen hands or feet
- Headache
- Muscle pain
- Depressed mood

Other side effects include:

- Unwanted non-scalp hair. This may be due to transfer of Women's GLN-MINOXIDIL to areas other than the scalp, or by absorption into the circulatory system of low levels of the active ingredient, or a medical condition not related to use of GLN-MINOXIDIL FOAM. Always wash your hands thoroughly after application and if you accidentally apply the foam to parts of the body other than the scalp, rinse thoroughly with plenty of water.
- Scalp irritation such as local redness, itchiness, dryness, and flaky skin have all been

reported. This is usually only a temporary effect, but if it lasts a long time, you should stop using this product.

- Temporary hair loss may occur during the first 2-6 weeks of use. If this hair loss continues for longer than 2 weeks, stop using the product and talk to your doctor.
- Change in hair colour and/or texture may occur. If this happens you should stop using Women’s GLN-MINOXIDIL.
- Women’s GLN-MINOXIDIL should be applied only to the scalp. The risk of side effects may be greater when it is applied to other parts of the body.

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
VERY RARE			
Swollen face, lips, mouth, tongue, and throat			✓
Skin redness, rash, severe irritation, throat tightness			✓
Chest pain			✓
Rapid or irregular heartbeat			✓
High or low blood pressure			✓
Shortness of breath or difficulty breathing			✓

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (canada.ca/drug-device-reporting) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

- Keep out of reach and sight of children.
- Store at a controlled room temperature range of 15-30°C, in an upright position.
- Do not use after the expiry date on the base of the can.
- The product in this pressurized container is extremely flammable, therefore exposure of the container or its contents to open flames should be avoided.
- Protect from sunlight and do not expose to temperatures above 50°C.
- Do not pierce or burn the container, even when empty.
- Do not use while smoking.
- Do not use near, or place container on, polished or painted surfaces.
- Medicines should not be disposed of via wastewater or household waste.
- Ask your pharmacist how to dispose of medicines no longer required.
- These measures will help to protect the environment.

If you want more information about Women's GLN-Minoxidil:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website: <https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>; or contacting Glenmark Pharmaceuticals Canada Inc. at 1-844-801-7468.

This leaflet was prepared by Glenmark Pharmaceuticals Canada Inc.

Date of Authorization March 05, 2025